Natural killer-cell lymphoma involving the gynecologic tract.
Non-Hodgkin lymphomas (NHL) can involve the gynecologic tract, most often as a manifestation of systemic involvement, and most cases reported have been of B-cell lineage. We describe 2 women with natural killer (NK)-cell lymphoma involving the gynecologic tract that initially presented with vaginal bleeding. In case 1, the patient had a stage IE nasal-type NK-cell lymphoma involving the cervix. The tumor was composed of medium-sized, irregular lymphoid cells with angioinvasion and necrosis. In case 2, the patient had a stage IV blastoid NK-cell lymphoma/leukemia infiltrating all organs in a hysterectomy and bilateral salpingo-oophorectomy specimen. Subsequent biopsy specimens revealed that the bone marrow and lymph nodes were also involved. The neoplasm was composed of small to medium lymphoid cells with fine nuclear chromatin. Case 1 was assessed immunohistochemically and the neoplastic cells were positive for CD3, CD56, and TIA-1. Case 2 was analyzed using both immunohistochemical and flow cytometry methods. The neoplastic cells were positive for cytoplasmic CD3, CD4, CD7, CD43, CD45, and CD56 and were negative for surface CD3. Both cases were negative for Epstein-Barr virus (EBV) ribonucleic acid (RNA) and molecular studies showed no evidence of T-cell receptor gamma chain gene rearrangements. The immunophenotype and absence of T-cell receptor gene rearrangements support NK-cell origin. We report these cases to illustrate that NK-cell lymphomas can involve, and rarely arise in, the gynecologic tract.
Mhawech
P
P
Departments of Pathology, University of Texas, M.D Anderson Medical Center, Houston, TX 77030, USA.
Medeiros
L J
LJ
Bueso-Ramos
C
C
Coffey
D M
DM
Gei
A F
AF
Shahab
I
I
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D002584:Cervix Uteri / Q000473:pathology*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007044:Hysterectomy; D007150:Immunohistochemistry; D007694:Killer Cells, Natural / Q000737:chemistry / Q000473:pathology*; D008223:Lymphoma / Q000737:chemistry / Q000473:pathology* / Q000628:therapy; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D002583:Uterine Cervical Neoplasms / Q000737:chemistry / Q000473:pathology* / Q000628:therapy; D014750:Vincristine / Q000627:therapeutic use
D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone